Sensei Biotherapeutics (SNSE) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on multi-node inhibition of oncogenic pathways to improve cancer patient outcomes.

• Acquired Faeth Therapeutics, adding PIKTOR, an all-oral combination therapy targeting the PI3K/AKT/mTOR pathway, to its pipeline.

• Lead program PIKTOR is in Phase 2 for endometrial cancer and planned for Phase 1b in advanced breast cancer.

• Pipeline includes additional preclinical and clinical programs, including conditionally active antibodies and metabolic pathway inhibitors.

Financial performance and metrics

• Raised approximately $200 million in gross proceeds from a private placement of Series B Preferred Stock at $13,850 per share ($13.85 per share as-converted to common stock).

• Acquisition of Faeth Therapeutics was a stock-for-stock transaction, with 10,497.098 Series B Preferred Shares issued, convertible into 10,497,098 common shares.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders; proceeds from warrant exercises, if any, will go to the company.

• Company will bear registration and listing costs, while selling stockholders cover their own transaction expenses.